Agency for Science, Technology and Research

Centre National De La Recherche Scientifique

Chugai Seiyaku Kabushiki Kaisha

Immupharma France Sa

Laurent Renia

Lisa Fong Poh Ng

Cheng-I Wang

Gilles Guichard

Katja Fink

Gersande R Lena

Anis Larbi

Lai Guan Ng

Guillaume Robert Carissimo

Immanuel Kwok Weng Han

Weili Xu

Wenn-Chyau Lee

Eliette Lallemand

Zenjiro Sampei

Xing'er Christine Xoo

Guichard Gilles

Gersande Lena

The invention relates to a composition comprising insulin growth factor binding protein 7 (IGFBP7) for treating malaria or reducing the phenomenon of IRB C-endothelial cytoadherence. The composition can further comprise Von Willebrand Factor (VWF) and/or thrombospondin-1 (TSP-1). The composition can also be used as an adjunct therapeutic agent alongside other anti-malarial drugs.

Use of IGFBP7 for treating malaria

There is provided a method of evaluating risk of severe outcome of an infectious disease and/or an inflammatory disease in a patient, the method comprising: determining/measuring the number of one or more immune cells selected from the group consisting of VD2 T cells, CD8 T cells, and immature neutrophils in a sample obtained from the patient, wherein the patient has an enhanced risk of severe infectious disease and/or inflammatory disease outcome when: (i) the ratio of immature neutrophils to VD2 T cell is at least 2:1, and/or (ii) the ratio of immature neutrophils to CD8 T cell is at least 0.5:1. Also disclosed are method of treating a patient with a severe infectious disease and/or inflammatory disease and kit for use in methods thereof.

Method of evaluating progression of an infectious disease and/or inflammatory disease

The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.

Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use

The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.

Compositions and methods for the treatment and prevention of disease

Growing community of inventors

Singapore, Singapore

Laurent Renia